Business
Final results for period ended 30 September 2025
RUA Life Sciences plc announced its final results for the period ended 30 September 2025, reporting a significant strategic achievement of doubling revenue to £6.7 million, a 104% like-for-like increase from £2.2 million in the prior 12-month period. The company also saw a substantial £2.0 million improvement in EBITDA, reaching £0.4 million from a £1.6 million loss, and reduced its loss before tax by 85% to £0.2 million. This performance was bolstered by the acquisition of ABISS, which contributed £5.8 million in CDMO revenues and a £0.9 million bargain purchase gain, alongside a 23% like-for-like growth in RUA Biomaterials revenue to £914,000. The company ended the period with £3.25 million in cash. Disclaimer*
About this update from Rua Life Sciences Plc
[{"type":"text","content":"\n\n \n \nRUA Life Sciences plc\n(\"RUA Life Sciences\", the \"Company\" or the \"Group\")\n \nFinal results for the period ended 30 September 2025\n \nRUA Life Sciences, a medical device focussed CDMO specialising in implantable textile components and devices and the exploitation of the world's leading long-term implantable biostable polymer (Elast-EonTM), announces its audited final results for the period ended 30 September 2025.\n Highlights:\n \n· Strategic objective of doubling revenue achieved with focus on growth and commercial activities.\n· Revenues for 18 months £6.7m (12 months to March 2024: £2.2m)\n· Like for like revenue growth of 104%\n· £2.0m improvement in EBITDA to £0.4m from £1.6m loss.\n· Loss before tax reduced 85% to £0.2m (2024: £2.0m)\n· CDMO business strengthened with bargain purchase of ABISS (£0.9m gain).\n· CDMO revenues £5.8m (FY24 £1.7m)\n· 23% like for like growth in RUA Biomaterials despite strength of Sterling against US dollar.\n· Biomaterials revenues £914,000 (FY24 £496,000).\n· Reduced R&D spend £438,000 (2024: £873,000)\n· Strategy to commercialise IP created in RUA Vascular and RUA Structural Heart being pursued\n· Year-end cash £3,250,000 (2024: £3,931,000)\n \nCurrent trading and outlook\nActivity levels achieved during period have continued into current year with encouraging new business pipelines.\n \n \nGeoff Berg, Chairman of RUA Life Sciences, commented: \"The two year objectives set at the time of the 2023 Strategy Review, of doubling revenues, reducing cash burn and focussing on profitability have been achieved ahead of time through strong trading and the purchase of the Abiss subsidiary in France. We look forward to building upon this success through broadening both services for current customers and expanding the customer base further\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under t...